Cue Biopharma Announces Proposed Public Offering
Cue Biopharma (Nasdaq: CUE), a clinical-stage biopharmaceutical company, has announced plans for an underwritten public offering of common stock shares and accompanying warrants. The company, which develops therapeutic biologics for cancer and autoimmune disease treatment, will also offer pre-funded warrants to purchase common stock as an alternative.
The offering will be managed by Oppenheimer & Co. Inc. as the sole book-running manager, with Newbridge Securities serving as co-manager. The offering's completion, size, and terms are subject to market conditions and cannot be guaranteed.
The securities will be offered under a shelf registration statement on Form S-3 (File No. 333-271786) that was filed with the SEC on May 9, 2023, and became effective on May 26, 2023. A preliminary prospectus supplement will be filed with the SEC.
Cue Biopharma (Nasdaq: CUE), un'azienda biofarmaceutica in fase clinica, ha annunciato piani per un'offerta pubblica garantita di azioni ordinarie e warrant associati. La società, che sviluppa biologici terapeutici per il trattamento di tumori e malattie autoimmuni, offrirà anche warrant prefinanziati per l'acquisto di azioni ordinarie come alternativa.
L'offerta sarà gestita da Oppenheimer & Co. Inc. come unico gestore principale, con Newbridge Securities come co-manager. Il completamento, la dimensione e le condizioni dell'offerta dipenderanno dalle condizioni di mercato e non possono essere garantiti.
I titoli saranno offerti nell'ambito di una dichiarazione di registrazione a sportello sul modulo S-3 (File No. 333-271786) depositata presso la SEC il 9 maggio 2023 e divenuta efficace il 26 maggio 2023. Verrà depositato un supplemento al prospetto preliminare presso la SEC.
Cue Biopharma (Nasdaq: CUE), una empresa biofarmacéutica en etapa clínica, ha anunciado planes para una oferta pública asegurada de acciones ordinarias y warrants asociados. La compañía, que desarrolla biológicos terapéuticos para el tratamiento del cáncer y enfermedades autoinmunes, también ofrecerá warrants prefinanciados para la compra de acciones ordinarias como alternativa.
La oferta será gestionada por Oppenheimer & Co. Inc. como único administrador principal, con Newbridge Securities como co-administrador. La finalización, el tamaño y los términos de la oferta estarán sujetos a las condiciones del mercado y no pueden garantizarse.
Los valores se ofrecerán bajo una declaración de registro en estantería en el Formulario S-3 (Archivo No. 333-271786) que fue presentado ante la SEC el 9 de mayo de 2023 y se hizo efectivo el 26 de mayo de 2023. Se presentará un suplemento preliminar al prospecto ante la SEC.
Cue Biopharma (나스닥: CUE)는 임상 단계의 바이오제약 회사로서 보통주 주식과 동반 워런트의 인수형 공개 발행 계획을 발표했습니다. 암 및 자가면역 질환 치료용 치료용 생물학 제제를 개발하는 이 회사는 대안으로 보통주를 구매할 수 있는 사전 자금 조달 워런트도 제공할 예정입니다.
이번 발행은 Oppenheimer & Co. Inc.가 단독 주관사로 관리하며, Newbridge Securities가 공동 주관사로 참여합니다. 발행 완료, 규모 및 조건은 시장 상황에 따라 달라질 수 있으며 보장되지 않습니다.
증권은 2023년 5월 9일 SEC에 제출되어 2023년 5월 26일 효력이 발생한 Form S-3(파일 번호 333-271786) 선반 등록 명세서에 따라 제공됩니다. 예비 증권 설명서 보충서가 SEC에 제출될 예정입니다.
Cue Biopharma (Nasdaq : CUE), une société biopharmaceutique en phase clinique, a annoncé son projet d'offre publique garantie d'actions ordinaires et de bons de souscription associés. La société, qui développe des biologiques thérapeutiques pour le traitement du cancer et des maladies auto-immunes, proposera également des bons de souscription préfinancés pour l'achat d'actions ordinaires en alternative.
L'offre sera gérée par Oppenheimer & Co. Inc. en tant que gestionnaire principal unique, avec Newbridge Securities en tant que co-gestionnaire. La réalisation, la taille et les conditions de l'offre dépendront des conditions du marché et ne peuvent être garanties.
Les titres seront proposés dans le cadre d'une déclaration d'enregistrement sur étagère selon le formulaire S-3 (dossier n° 333-271786) déposé auprès de la SEC le 9 mai 2023 et devenu effectif le 26 mai 2023. Un supplément au prospectus préliminaire sera déposé auprès de la SEC.
Cue Biopharma (Nasdaq: CUE), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat Pläne für ein öffentliches Angebot von Stammaktien und begleitenden Warrants unter Zeichnungsgarantie angekündigt. Das Unternehmen, das therapeutische Biologika zur Behandlung von Krebs und Autoimmunerkrankungen entwickelt, wird auch vorfinanzierte Warrants zum Kauf von Stammaktien als Alternative anbieten.
Das Angebot wird von Oppenheimer & Co. Inc. als alleinigem Lead-Manager geleitet, mit Newbridge Securities als Co-Manager. Abschluss, Umfang und Bedingungen des Angebots hängen von den Marktbedingungen ab und können nicht garantiert werden.
Die Wertpapiere werden im Rahmen einer Shelf-Registrierungserklärung auf Formular S-3 (Aktenzeichen 333-271786) angeboten, die am 9. Mai 2023 bei der SEC eingereicht und am 26. Mai 2023 wirksam wurde. Ein vorläufiger Prospektergänzung wird bei der SEC eingereicht.
- Access to new capital through public offering to support operations
- Established underwriting support from Oppenheimer & Co. Inc.
- Potential dilution of existing shareholders through new stock issuance
- Uncertain offering terms and completion timeline
- No specified amount of capital to be raised
Insights
Cue Biopharma's announced public offering represents a significant capital event for this micro-cap biotech currently valued at just
The lack of details regarding offering size, pricing, or intended use of proceeds creates uncertainty for investors. However, the fundamental reality for clinical-stage biopharmaceutical companies remains consistent: they require regular capital infusions to fund R&D and clinical trials until reaching commercialization.
For existing shareholders, this offering will almost certainly result in dilution, particularly concerning for a company already trading below
The engagement of Oppenheimer as book-runner suggests institutional backing, providing some validation. Investors should closely monitor the preliminary prospectus filing for critical details on pricing, size, and proceeds allocation that will determine the true impact on shareholder value and operational runway.
This financing announcement comes at a critical juncture for Cue Biopharma as they advance their novel therapeutic biologics platform targeting selective T cell engagement. While dilutive to existing shareholders, capital raises represent an essential lifeline for clinical-stage biotechs with promising technology but distant revenue horizons.
Cue's technological approach - selectively engaging and modulating disease-specific T cells - addresses significant limitations in current immunotherapies by potentially reducing off-target effects while maintaining therapeutic efficacy across both oncology and autoimmune indications. This differentiated mechanism represents meaningful innovation in a competitive immunotherapy landscape.
For development-stage companies like Cue, the ability to extend operational runway through capital raises directly correlates with reaching value-inflection clinical milestones that validate their platform technology. While the announcement doesn't specify which pipeline programs will benefit from this financing, the additional capital should enable continued advancement of clinical trials necessary to demonstrate proof-of-concept.
The market's ultimate reaction will depend on both the specific offering terms and investors' assessment of Cue's clinical progress to date. The dual-track focus on both cancer and autoimmune applications provides multiple potential paths to success, though each requires substantial investment to reach meaningful clinical readouts that could attract partnership interest or justify further financing rounds.
BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced that it is commencing an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the securities are being offered by Cue Biopharma.
Oppenheimer & Co. Inc. is acting as sole book-running manager for the offering. Newbridge Securities Corporation is acting as co-manager for the offering.
A shelf registration statement on Form S-3 (File No. 333-271786) relating to the securities to be offered in the public offering was filed with the Securities and Exchange Commission (the “SEC”) on May 9, 2023, and declared effective on May 26, 2023. The offering will be made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. When available, copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering may also be obtained by contacting: Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, New York 10004, by telephone at (212) 667-8055, or by email at EquityProspectus@opco.com.
This press release does not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells), and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation.
Headquartered in Boston, Massachusetts, we are led by an experienced management team with deep expertise in immunology and protein engineering as well as the design and clinical development of protein biologics.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those regarding: the proposed public offering, including the completion of the public offering on the anticipated terms, or at all. Forward-looking statements, which are based on certain assumptions and describe the company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “goal,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “strategy,” “future,” “vision,” “should,” “target,” “will,” “would,” “likely” or other comparable terms, although not all forward-looking statements contain these identifying words.
Cue Biopharma may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on its forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Cue Biopharma makes as a result of various risks and uncertainties, including but not limited to market and other financial conditions, satisfaction of customary closing conditions related to the proposed public offering, Cue Biopharma’s limited operating history, limited cash and a history of losses, Cue Biopharma’s ability to achieve profitability, Cue Biopharma’s ability to obtain adequate financing to fund its business operations in the near-term, Cue Biopharma’s ability to successfully remediate its current “going concern” determination that it does not have sufficient capital on hand to continue operations beyond the next twelve months, Cue Biopharma’s reliance on licensors, collaborators, contract research organizations, suppliers and other business partners, potential setbacks in Cue Biopharma’s research and development efforts including negative or inconclusive results from its preclinical studies or clinical trials or Cue Biopharma’s ability to replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates and other risks and uncertainties described in the Risk Factors and Management's Discussion and Analysis of Financial Condition and Results of Operations sections of Cue Biopharma’s most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Reports on Form 10-Q. Any forward-looking statement made by Cue Biopharma in this press release is based only on information currently available to Cue Biopharma and speaks only as of the date on which it is made. Cue Biopharma undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Investor Contact
Marie Campinell
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com
Media Contact
Jonathan Pappas
LifeSci Communications
jpappas@lifescicomms.com
FAQ
What type of securities is Cue Biopharma (CUE) offering in its public offering?
Who are the managers for Cue Biopharma's (CUE) public offering announced in April 2025?
When was Cue Biopharma's (CUE) shelf registration statement declared effective by the SEC?
What is the primary focus of Cue Biopharma's (CUE) therapeutic development?
